CL2023000121A1 - Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas - Google Patents

Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas

Info

Publication number
CL2023000121A1
CL2023000121A1 CL2023000121A CL2023000121A CL2023000121A1 CL 2023000121 A1 CL2023000121 A1 CL 2023000121A1 CL 2023000121 A CL2023000121 A CL 2023000121A CL 2023000121 A CL2023000121 A CL 2023000121A CL 2023000121 A1 CL2023000121 A1 CL 2023000121A1
Authority
CL
Chile
Prior art keywords
antibodies
treatment
neutrophilic dermatoses
neutrophilic
present
Prior art date
Application number
CL2023000121A
Other languages
English (en)
Inventor
Fine Jay
Lamar Janine
John Padula Steven
Ramanujam Meera
Visvanathan Sudha
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2023000121A1 publication Critical patent/CL2023000121A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona métodos para tratar, prevenir o mejorar una dermatosis neutrófila. Los métodos de la presente invención incluyen administrar a un paciente que tiene una dermatosis neutrófila una composición farmacéutica que incluye un anticuerpo contra el receptor de interleucina 36 (anti-IL-36R).
CL2023000121A 2020-07-17 2023-01-12 Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas CL2023000121A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063053129P 2020-07-17 2020-07-17

Publications (1)

Publication Number Publication Date
CL2023000121A1 true CL2023000121A1 (es) 2023-09-08

Family

ID=77265246

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023000121A CL2023000121A1 (es) 2020-07-17 2023-01-12 Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas

Country Status (12)

Country Link
US (1) US20220073628A1 (es)
EP (1) EP4182022A1 (es)
JP (1) JP2023534955A (es)
KR (1) KR20230038774A (es)
CN (1) CN116745315A (es)
AU (1) AU2021309957A1 (es)
BR (1) BR112022026999A2 (es)
CA (1) CA3188382A1 (es)
CL (1) CL2023000121A1 (es)
MX (1) MX2023000763A (es)
TW (1) TW202225190A (es)
WO (1) WO2022015920A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240084021A1 (en) * 2021-01-08 2024-03-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2780373T3 (da) 2011-11-16 2019-11-04 Boehringer Ingelheim Int Anti-IL-36R-antistoffer
CA2982555A1 (en) * 2015-04-15 2016-10-20 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (il-36r)
CN112272674A (zh) * 2018-03-14 2021-01-26 勃林格殷格翰国际有限公司 抗-il-36r抗体用于治疗泛发性脓疱性银屑病的用途
WO2020018511A1 (en) * 2018-07-16 2020-01-23 Regeneron Pharmaceuticals, Inc. Non-human animal models of ditra disease and uses thereof
BR112021010789A2 (pt) * 2018-12-27 2021-08-31 Boehringer Ingelheim International Gmbh Anticorpos anti-il-36r para o tratamento de pustulose palmoplantar
JP7420827B2 (ja) * 2019-03-08 2024-01-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ－３６ｒ抗体製剤
BR112023017717A2 (pt) * 2021-05-03 2024-01-09 Boehringer Ingelheim Int Método para produção de espesolimabe

Also Published As

Publication number Publication date
BR112022026999A2 (pt) 2023-01-24
CN116745315A (zh) 2023-09-12
KR20230038774A (ko) 2023-03-21
WO2022015920A1 (en) 2022-01-20
MX2023000763A (es) 2023-02-13
CA3188382A1 (en) 2022-01-20
TW202225190A (zh) 2022-07-01
AU2021309957A1 (en) 2023-02-02
JP2023534955A (ja) 2023-08-15
EP4182022A1 (en) 2023-05-24
US20220073628A1 (en) 2022-03-10

Similar Documents

Publication Publication Date Title
DOP2019000280A (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso
CL2020002075A1 (es) Métodos para tratar el cáncer con anticuerpos anti-pd1.
DOP2019000020A (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
CL2019000266A1 (es) Composición de cannabis.
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
CO2023015484A2 (es) Compuesto, composiciones y métodos para el tratamiento de trastornos
BR112021019334A2 (pt) Anticorpos de cadeia pesada que se ligam ao psma
CO2017001875A2 (es) Terapia de combinación contra el alzheimer usando anticuerpos anti-n3pglu más un inhibidor bace
CO2021008665A2 (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r
CL2020002465A1 (es) Método de tratamiento de enfermedad fibrótica
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
CL2023000121A1 (es) Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas
BR112022020643A2 (pt) Método de tratamento de esteato-hepatite não alcoólica
CO2021009129A2 (es) Tubulisinas y conjugados de proteína-tubulisina
BR112021021713A2 (pt) Método de tratamento de câncer ou inibição do crescimento de um tumor
CO2023002375A2 (es) Anticuerpos contra ilt2 y uso de los mismos
CL2023003073A1 (es) Anticuerpos anti-cd20 y estructuras car-t
DOP2021000215A (es) Tratamiento de la cefalea usando anticuerpo anti-cgrp
CL2021000892A1 (es) Avexitida para el tratamiento de la hipoglucemia hiperinsulinémica
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
BR112021023906A2 (pt) Método para fornecer administração segura de um anticorpo anti-cd40
BR112023026992A2 (pt) Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia do medicamento em uma composição farmacêutica e método para tratar e/ou prevenir o câncer
CL2022000091A1 (es) Métodos para tratar la pancreatitis. (divisional de solicitud n° 202100585)
AR125296A1 (es) Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1
CL2022002829A1 (es) Anticuerpo anti-ox40 y usos del mismo